cilengitide has been researched along with Cells, Neoplasm Circulating in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Hawary, M; Bradley, DA; Chen, A; Cooney, KA; Daignault, S; Dipaola, RS; Doyle, G; Escara-Wilke, J; Gross, ME; Hussain, M; Keller, ET; Mathew, P; Pienta, KJ; Ryan, CJ; Small, E; Smith, DC; Stein, MN | 1 |
| Agus, D; Alva, A; Carducci, M; Chen, A; Cooney, K; Daignault, S; Dipaola, R; Hussain, M; Pienta, K; Slovin, S; Smith, DC | 1 |
2 trial(s) available for cilengitide and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Collagen Type I; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Snake Venoms; Time Factors; Treatment Outcome | 2011 |
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Infusions, Intravenous; Integrin alphaVbeta3; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Vitronectin; Snake Venoms; Time Factors; Treatment Failure; United States | 2012 |